# Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia

Source: https://onco.cc/trials/nct06224257/  
OnCo record `nct06224257` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Linperlisib in Leukaemia, run by Institute of Hematology & Blood Diseases Hospital, China, now recruiting.

## Summary

Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia is a phase 2 interventional study registered as NCT06224257 by Institute of Hematology & Blood Diseases Hospital, China, with 41 participants planned, started 2023-12-03 and due to reach its primary completion in 2025-10-31. Interventions recorded: Linperlisib. Conditions recorded: Relapsed/Refractory Large Granular T Lymphocytic Leukemia.

Linked to the drug Linperlisib because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06224257
- Phase: 2
- Setting: A Phase 2, Multicenter, Single-arm, Open-label Study on the Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
- Sponsor: Institute of Hematology & Blood Diseases Hospital, China
- Enrolled: 41

## Sources

- ClinicalTrials.gov NCT06224257: https://clinicaltrials.gov/study/NCT06224257

## Connected records

- cancers: [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/)
- drugs: [Linperlisib](https://onco.cc/drugs/linperlisib/)

---
JSON: https://onco.cc/api/v1/entities/nct06224257.json